359 / 671
Prognostic factors related to survival after SBRT for mCRC
MM Fode et al. Radiother Oncol 2015; 114(2):155
Covariate
Categories (n)
Median OS years
(95 % CI)
HR
P- value
Performance status
0-1 (187)
2-3 (14)
2.5 (2.1 – 2.8)
1.2 (0.3- 1.9)
2.54
<0.01
Gender
Males (136)
Females (65)
3.0 (2.4-3.6)
3.5 (2.8-4.2)
0.65
0.03
Age
<71 (101)
>72 (100)
3.2 (2.6-3.8)
2.9 (2.6-3.6)
1.10
0.38
Size of largest metastases
≤ 30 mm (102)
>30 mm (98)
2.8 (2.5 – 3.4 )
1.9 (1.5 – 2.1)
1.67
<0.01
Number of metastases
1 metastasis (86)
2-6 metastases (115)
2.8 (2.3 – 3.4)
2.0 (1.8 – 2.5)
1.49
0.02
Treatment site
Lung (30)
Liver, other (171)
3.4 (2.3 – 5.1 )
2.1 ( 1.9– 2.6)
1.74
0.03
Prior chemotherapy
Yes (132)
No (69)
2.6 (2.0 – 3.2)
2.1 (1.3 – 2.5)
1.44
0.03
Prior local therapy
Yes (98)
No (103)
2.6 (2.0- 2.8)
2.1 (1.9- 2.8)
1.16
0.39
Timing of metastasis
Metachronous (70)
Synchronous (131)
2.5 (2.0 – 3.3)
2.3 (1.8 – 2.7)
1.14
0.48